FDA - Washington Examiner

Studies show not taking medications as prescribed leads to poorer health, more frequent hospitalization, a higher risk of death and as much as $290 billion annually in increased medical costs.ÃÂ But as any health care provider will tell you, the fact that actually taking a medication as prescribed is in a patientÃ¢â¬â¢s best interest does not lead to a patient doing what is in his best interest. (Photo: Thinkstock)

Op-Eds

Grandstanding AGs sue to stop drugmaker’s work to insure patients take medicine properly

Peter Pitts -

January 14, 2014 5:00 am

News

FDA approves diabetes drug with new approach

Matthew Perrone -

January 8, 2014 6:01 pm

News

Feds crack down on 4 bogus weight loss aids

Matthew Perrone -

January 7, 2014 8:40 pm

Regulations are preventing a number of startup companies from providing patients with access to potentially vital genetic information. (Thinkstock)

Healthcare

Red tape stifles genetics-based advances in women’s health

Bethany Mandel -

January 6, 2014 5:00 am

FDA Seeking Gum Chewing Tester

Jeryl Bier -

January 3, 2014 1:29 pm

Sean Azzariti, a former Marine who served in the Iraq war and has post-traumatic stress disorder, shakes hands and thanks store owner Toni Fox, after Azzariti was the first to buy retail marijuana at 3D Cannabis Center, which opened as a legal recreational retail outlet in Denver on Jan. 1. (AP/Brennan Linsley)

Legal weed sales bring long lines to Colorado

Kristen Wyatt -

January 2, 2014 5:00 am

Fewer teens are trying fake marijuana known by such names as K2 and Spice, apparently getting the message that these cheap new drugs are highly dangerous, according to the government's annual survey on drug use. (AP/Ted S. Warren)

National Security

Survey: Teens using synthetic drugs less often

Alicia Caldwell -

December 18, 2013 5:00 am

Technology

FDA raises safety concerns on antibacterial soaps

Washington Examiner -

December 16, 2013 5:00 am

Magazine

The FDA vs. Information

The Scrapbook -

December 9, 2013 5:00 am

When it comes to biosimilars, we need to be extremely thoughtful about how we set policy relating to these promising medicines and strike a balance that promotes health and safety, rather than forcing a binary response that is driven by profits rather than patients. (Photo: Thinkstock)

Op-Eds

FDA must decide if a biosimilar rose by any other name is still a rose

Peter Pitts -

December 9, 2013 5:00 am

1...174175176...180 Page 175 of 180

Tag: FDA